Clinical Trial

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-07-07; most recent amendment 2025-10-27.
Status change: Recruiting → Active, Not Recruiting 2025-10-27
Trial Details
NCT Number NCT05938725
Lead Sponsor Kyverna Therapeutics
Conditions Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Enrollment 6 participants
Start Date 2023-04-28
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-29